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Hydrazinyldiene-chroman-2,4-diones in inducing growth arrest 
and apoptosis in breast cancer cells: Synergism with doxorubicin 
and correlation with physicochemical properties
This study evaluates the effects of previously synthe-
sized hydrazinyldiene-chroman-2,4-diones on cell 
proliferation and apoptosis, cell cycle distribution and 
migration capacity of MCF-7 breast cancer cells in syn-
ergy with doxorubicin. Physicochemical properties of 
the synthesized compounds were correlated with 
their structure and activity. Significant cell viability 
decrease in comparison with the effect of doxorubicin 
alone and the reference 4-hydroxycoumarin was ob-
served when combination treatment comprising doxo-
rubicin and the title compounds was applied. Syner-
gistic effect with doxorubicin was also observed in 
down-regulation of phospho-Thr308Akt levels, con-
firming reduced proliferation and increased apopto-
sis. Combined treatment increased the percentage of 
cells arrested at the G2/M stage. Additive inhibition of 
cell migration was also observed, pointing to the pos-
sibility of reducing the risk of metastases. With their 
solubility profile and log D7.4, all the synthesized com-
pounds follow Lipinski’s rule of five for good perme-
ability (absorption) potential.
Keywords: hydrazinyldiene-chroman-2,4-diones, physi-
cochemical properties, doxorubicin, cytotoxicity, 
breast cancer cells
Breast cancer is a heterogeneous disease involving different molecular subtypes, oc-
curring and remaining within its original location and/or spreading outside the breast to 
other organs of the body such as the lungs, distant lymph nodes, skin, bones, liver or brain. 
Over one million of new breast cancer patients are diagnosed each year, accounting for 
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16 % of all female cancers, 23 % of invasive cancers in women and 18 % of all cancer deaths 
worldwide for both males and females (1). Depending on the pathology and biology of the 
disease and patient characteristics, different strategies are applied to manage the disease 
and control the mortality, including surgery and radiation therapy as well as systemic 
endocrine, cytotoxic and biological/targeted therapies, employed in various combinations 
and sequences. However, severe toxic side effects and resistance to available therapies oc-
cur and are a strong motivation to the researchers to design and develop novel medicines 
and explore novel therapeutic combinations.
For many decades, anthracycline doxorubicin (Doxo) has been proven to be effective for 
early, locally advanced and inflammatory breast cancer as well as metastatic and recurrent 
one, killing cancer cells by intercalation into DNA and disruption of topoisomerase-II-me-
diated DNA repair and by generation of free radicals that damage cellular membranes, DNA 
and proteins. However, because of the fear of long-term cardiotoxicity, this drug is included 
in adjuvant regimens. In addition, resistance to Doxo, occurring as a multifactorial phenom-
enon, causes an incomplete response requiring combination chemotherapy (2).
Search for new agents against breast cancer that could also improve the therapeutic 
index of available anticancer medicines led us to coumarin coupled with isoxazole and 
thiazole moieties (3). Coumarin skeleton has been selected due to the antioxidant proper-
ties of coumarins and their effects on immune responses, cell growth and differentiation, 
specifically in breast cancer (4, 5). Structure-activity studies pointed to three functional 
groups in the coumarin core as essential for the inhibition of aromatase, 3-(4-chlorophe-
nyl), 4-benzyl and 7-methoxy (4), while tricyclic coumarin-based sulfamates have been 
singled out as alternative inhibitors of steroid sulfatase, (5). In addition, 3,4-disubstituted 
coumarin derivatives have been proposed as selective estrogen receptor modulators (6), 
with 3-substituted coumarins further used for coupling with cytotoxic agents and biocon-
jugation with estradiol to improve selectivity (7). Thiazoles and isoxazoles are already 
proven precursors in the synthesis of medicinal compounds and heterocycles derived 
from them are widely evaluated in respect to their antiproliferative and tumor vascular-
disrupting activities. It has been recently shown that thiazole antibiotics could suppress 
tumor growth in a human breast cancer xenograft, and repression of FoxM1 expression 
and proteasome inhibition was proposed as a mechanism of activity (8). Certain isoxazole 
derivatives were characterized as inhibitors of АТР р38α mitogen activated protein kinase 
(MAPK), casein kinase 1δ, STAT3 phosphorylation and inhibitors of other targets for che-
motherapy (9). In this respect, isoxazole analogue of curcumin has shown significant an-
titumor activity in the MCF-7 breast cancer cell line and its multidrug-resistant variant 
MCF-7R, being more potent (approximately twofold) compared to curcumin alone (10).
Considering all the above-mentioned information, compounds that combine couma-
rin core and isoxazoles or thiazoles in hydrazinyldiene-chroman-2,4-diones have been 
synthesized and structurally characterized in our previous studies (Table I) (3, 11, 12). 
Three compounds having thiazole moiety, 3-[2-(1,3-thiazol-2-yl)hydrazinylidene]chroman-
2,4-dione (1c), 3-[2-(4-methyl-1,3-thiazol-2-yl)hydrazinylidene]chroman-2,4-dione (1d) and 
3-[2-(4,5-dimethyl-1,3-thiazol-2-yl)hydrazinylidene]chroman-2,4-dione (1e), have been 
shown to exert more potent antiproliferative activity than the other synthesized com-
pounds, inducing apoptosis in breast cancer cells MCF-7 and MDA-MB-231 (3) and in bone 
and lung metastatic cell lines from breast cancer SCP1833 and SCP4175 (11). In this study, 
the synergistic effects of these three hydrazinyldiene-chroman-2,4-diones and Doxo on 
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cell proliferation and apoptosis, cell cycle distribution and migration capacity of breast 
cancer cell lines MCF-7 were evaluated. In addition, their physicochemical properties were 
determined and correlated with their structure and IC50 values.
EXPERIMENTAL
Cell culturing
Human breast cancer MCF-7 cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, USA) and were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen, Switzerland) containing 10 % fetal bovine serum (FBS, Invi-
trogen), supplemented with glutamine (0.03 %, m/V) and 100 µg mL–1 benzyl penicillin, 100 
U mL–1 streptomycin and 2.5 µg mL–1 amphotericin (all obtained from Invitrogen). Cells 
were allowed to grow in tissue culture flasks (Corning, USA) and were kept in a CO2 incu-
bator at 37 °C in a humidified atmosphere with 5 % CO2 and 95 % air. For experimental 
purposes, cells from exponentially growing cultures were used. 
Cell viability assays
For viability assays, 4-hydroxycoumarin (4-HC) (Merck, Germany), synthesized com-
pounds (Table I; 1c, 1d, 1e) and Doxo (Sigma-Aldrich, USA) were dissolved in dimethyl 
sulfoxide (DMSO, Sigma-Aldrich) to get 10 mmol L–1 stock solutions and were stored at 
–20 °C. Further dilutions were made in complete DMEM containing 10 % FBS. Cytotoxic 
effects of coumarin derivatives and 4-HC alone and in synergy with Doxo on MCF-7 cells 
were determined in 96-microwell plates by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphen-
yltetrazolium bromide] and alamarBlue assay as previously described (3, 11, 13).
In the MTT assay, 100 µL of growth medium (DMEM) was poured into each well of a 
96-well plate plated with 5 × 103 MCF-7 cells per well. Cells were allowed to attach over-
night and were then treated with the solutions of reference and synthesized compounds 
in increasing concentrations (0.01, 0.02, 0.05, 0.1 mmol L–1), alone and in the presence of 
Table I. Structure of synthesized hydrazinyldiene-chroman-2,4-diones (refs. 3, 12, 13)
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Compound X Y R1 R2 R3
1a N N H H H
1b O C CH3 H
1c C S H H
1d C S H CH3
1e C S CH3 CH3
1f O C terc-butyl H
1g C S H Br
1h O C H H
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Doxo (1 µmol L–1). After 48-h incubation at 37 oC, 5 % CO2 and relative humidity 95 %, 20 
µL (5 mg mL–1) of the MTT reagent was added to each well and incubated for additional 4 
h at 37 oC. After that, 100 µL of solvent, consisting of 4 mmol L–1 HCl (Sigma-Aldrich) and 
0.1 % octylphenoxypolyethoxy ethanol (Nonidet P-40, AppliChem, Germany) in isopropa-
nol (Sigma-Aldrich) was added to each well to solubilize the MTT crystals. The plates were 
covered with a foil and cells were agitated on an orbital shaker for 15 min. Absorbance was 
then read at 590 nm in a microplate reader (SpectraMax M2 fluorometer, BucherBiotec Inc., 
USA). All experiments were performed at least three times, with four wells for each con-
centration of the agents tested. Control cells (C) were grown under the same conditions 
without addition of test compounds. In the alamarBlue assay, after the same period and 
incubation conditions, 10 µL of alamarBlue reagent (10 % alamarBlue, Invitrogen) were 
added to each well and incubated for further 4 h at 37 oC. The plates were exposed to an 
excitation wavelength of 530 nm and the emission at 590 nm was read with a microplate 
reader. The percentage of viability was expressed as fluorescence counts in the presence of 
the tested compounds as a percentage of that in the vehicle control.
Western blot analysis
MCF-7 cell lines were treated for 48 h with either vehicle (0.05 % DMSO) or the indi-
cated concentration of the reference (Doxo, 1 µmol L–1) and synthesized compounds (20, 50 
and 100 µmol L–1). Treated cells were homogenized in a lysis buffer [25 mmol L–1 Tris-HCl, 
pH 7.5, 150 mmol L–1 NaCl, 1 % NP-40, 1 mmol L–1 EDTA, pH 8.0, 1 mmol L–1 PMSF (phenyl-
methylsulfonyl fluoride), 1 mmol L–1 Na3VO4 and 1× protease inhibitor cocktail-P2714, 
Sigma-Aldrich], centrifuged for 10 min at 14 000×g and the supernatant was taken for pro-
tein determination. Equal amounts of protein (30 µg) were separated on SDS-PAGE and 
transferred to nitrocellulose membranes. Western blot analysis was performed as previ-
ously described (3, 13) using antibodies against PARP [poly (ADP-ribose) polymerase], 
phospho-Thr308 Akt and the house-keeping protein GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase). Secondary antibodies coupled to horseradish peroxidase were from GE 
Healthcare Life Sciences (Sweden). Signals were detected by enhanced chemilumines-
cence (ECL Western blotting substrate, Thermo Fisher Scientific, USA) on photosensitive 
film (ECL Hyperfilm, GE Healthcare Life Sciences).
Flow cytometric analysis
Cell cycle distribution was assayed by flow cytometry after DNA staining with prop-
idium iodide (PI, Sigma-Aldrich). MCF-7 treated cells were trypsinized with trypsin-EDTA 
solution 1x (0.05 % trypsin, 0.02 % EDTA, Sigma-Aldrich) and washed with a protein-
containing phosphate buffered saline (PBS 10× concentrate diluted to 1× concentration + 5 
% fetal bovine serum, Sigma-Aldrich) and centrifuged at 1100×g for 10 min. Cell pellets 
were re-suspended in 500 µL PBS containing 5 % FBS and centrifuged at 2000×g for 7 min 
at 4 °C, then fixed in 70 % ethanol and stored overnight at –20 oC. Fixed cells were washed 
with PBS, incubated with 25 µg mL–1 RNase (Merck) at 37 °C for 30 min and then stained 
with 50 µg mL–1 PI. The samples were then incubated at 4 °C in dark for 1 h and flow cyto-
metric analyses were performed using a BD FACSCaliburTM (BD Biosciences, USA) instru-
ment. The fraction of the total cell population present in the phases: S (phase of DNA 
synthesis), G1 (gap between the mitosis that gives rise to the cell and S phase) and the 
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phase of transition from G2 (gap between the S phase and mitosis that gives rise to two 
daughter cells) to M (the phase of mitosis) (G2/M phase) and the polyploidy peak was ob-
tained from DNA histograms by mathematical modeling using Cell Quest software (v. 
3.3; Becton Dickinson Biosciences, Switzerland). At least 20,000 cells were counted for 
each sample. Results from three independent experiments with three replicates per 
experiment were pooled.
Scratch-wound migration assay
MCF-7 cells were plated in 24-well-plates and when they grew into full confluence, a 
wound was induced onto monolayer cells by scraping a gap using a micro-pipette tip (100 
µL). Then, the compounds in different concentrations (0.01, 0.02, 0.05, 0.1 mmol L–1), alone 
or with Doxo (1 µmol L–1), were immediately added and maintained for 24 h. The speed of 
wound closure of treated and untreated cells was compared. Photographs were taken un-
der 10× magnification using phase-contrast microscopy (Zeiss Microscopy, Germany) im-
mediately after wound incision and at later time points. The gap distance was quantita-
tively evaluated using ImageJ software (v. 1.48; Wayne Rasband, NIH, USA) measuring the 
scratch area at 0 h and 24 h after incubation. Data are expressed as area reduction from 
time points 0 to 24 h. The results were pooled from three independent experiments with 
three replicates per experiment.
Determination of physicochemical properties
Solubility of the reference compound and synthesized compounds was determined 
in water and in a phosphate buffer solution (PBS, NaH2PO4, 0.25 mol L
–1, pH 7.4) using a 
static equilibrium method. An excess of the compound was exposed to the solvent, the 
mixtures were allowed to be stirred in a thermostatic water bath at 37 ± 1 oC (SWB 20, 
Haake, USA) and the samples were collected and assayed once, every 5 hours, and repli-
cated three consecutive times. Afterwards, the supernatant solutions previously obtained 
by ultracentrifugation at 12,000 rpm for 15 min were filtered to ensure that they were free 
of particulate matter before sampling. Concentration was determined by UV/VIS absorp-
tion at λmax 285 nm for 4-HC, 405 nm for 1b, 410 nm for 1c and 420 nm for 1d (Shimadzu 
UV – 1800, Japan), after appropriate dilution and interpolation from previously construct-
ed calibration curves for each compound. All the solubility experiments were repeated at 
least three times and the mean values were regarded as the measured results.
Distribution coefficients (log D7.4exp) between n-octanol and PBS (NaH2PO4, 0.25 mol L–1, 
pH 7.4) were determined by the shake-flask method. The reference and synthesized com-
pounds were dissolved in equal volumes of DMSO and EtOH (p.a. 96 % ethanol, Alkaloid, 
Macedonia) at a concentration of approx. 1 mg mL–1 to obtain the stock solution. The 
amounts of samples were chosen so that absorption of 0.2 to 0.8 in the water phase was 
reached after partitioning. The experiments were performed in the system n-octanol/PBS 
(1:2, V/V). An adequate volume of the stock solution was added to a mixture of the organic 
and aqueous phases (mutually saturated by previous shaking for 24 h at the temperature 
of the experiment) and placed into a glass vial. The phases were shaken together on the 
same mechanical shaker for 2 h at 25 ± 0.1 oC. Equilibration was generally reached within 
half an hour. After equilibration, the mixture was centrifuged for 10 min at 5000 rpm, the 
octanol phase was removed and the concentration of the compound was assayed in both 
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phases spectrophotometrically at λmax 290 nm for 4-HC, 405 nm for 1c, 410 nm for 1d and 
420 nm for 1e. Distribution coefficients were calculated as the ratio between the molar 
concentration in n-octanol and the aqueous phase. All experiments were done in triplicate.
For determination of pKa values, pH metric titration and the UV/Vis spectrophotomet-
ric method were applied. For the pH metric method, the compounds were dissolved sepa-
rately in acetonitrile (10–3 mol L–1) and then the solutions were diluted 1:100 with PBS (pH 
7.4, 10 mmol L–1, 8.0 g NaCl, 1.16 g K2HPO4, 0.2 g KH2PO4 and 0.2 g KCl in up to 1 L deion-
ized water) and mixed with a magnetic stirrer during titration. Titration was carried out 
in triplicate at ambient temperature of 23 ± 1 oC to ensure reproducibility using a pH meter 
(Sartorius PB-20, Sartorius AG, Germany) with declared accuracy of ± 0.01 and tempera-
ture corrections. pKa values were estimated from the graph constructed from the depen-
dence of dpH/dV vs. HCl volume. For the second method, the UV/Vis spectra of the inves-
tigated compounds (~10–5 mol L–1) and an appropriate blank were recorded in a pH range 
1 to 7, with 0.5 increments. The UV/Vis spectra were recorded, immediately after preparing 
the solutions, on a Varian Cary 50 Spectrophotometer (Varian Inc., USA) in 1-cm quartz 
cells, in the range from 190 to 650 nm, with resolution of 0.5 nm and scan rate of 300 nm 
min–1 at room temperature.
Experimental values of water solubility were compared with the calculated ones, ob-
tained with ALOGPS 2.1 software (VCCLAB, Virtual Computational Chemistry Labora-
tory,, Germany; http://www.vcclab.org; last access date January 15, 2016), while those of the 
other physicochemical parameters with ChemAxon’s software (ChemAxon, Hungary, 
www.chemaxon.com/products/calculator-plugins/property-predictors; last access date 
January 15, 2016).
Data presentation and statistical analysis
Cell survival was calculated relative to the controls. The 50 % inhibitory concentration 
(IC50) was determined as the anticancer drug concentration causing 50 % reduction in cell 
viability and was calculated from the viability curves by linear interpolation between the 
values immediately above and below the 50 % inhibition using the Bliss software (Bliss Co, 
Castro Valley, CA, USA). The results were presented as mean ± SD and the statistical anal-
ysis was performed using the one-way analysis of variance (ANOVA) followed by Bonfer-
roni’s post hoc test for multiple comparisons (GraphPadInStat version 3.00 for Windows NT, 
GraphPad Software, San Diego, CA, USA).
RESULTS AND DISCUSSION
Cytotoxic and antiproliferative effects of synthesized hydrazinyldiene-chroman-2,4-dio-
nes and doxorubicin
Effects of the coumarin derivatives 4-HC and Doxo on MCF-7 cell viability, alone or in 
combination, evaluated by MTT and alamarBlue assays, are presented in Figs. 1a and b, 
respectively. No significant difference in antiproliferative effect of Doxo on the MCF-7 cells 
was observed when the two assays were compared, with cell viability being preserved 
approx. 61 % when Doxo (1 µmol L–1) was administered. However, similarly to a previous 
study, in which synergy between coumarin derivatives and tamoxifen in blocking the 
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growth of MCF-cells was evaluated (13), non-significant differences in cell viability were 
observed when the data from the MTT and alamarBlue assays were compared, with the 
percentages of viable cells being higher in the MTT assay. For example, 4-HC alone in-
duced no apoptosis at concentration ≤ 20 µmol L–1 when the alamarBlue assay was applied, 
with cell viability slightly decreasing (approx. 7 %) when the concentration was increased 
to 100 µmol L–1 (Fig. 1b). However, when the MTT assay was applied, using the same con-
centration, the decrease in cell viability was more than 13 % (Fig. 1a). Also, for the synthe-
sized coumarin derivatives, higher cell viability was observed in the alamarBlue assay, 
Fig. 1. Effects of Doxo, 4-HC and synthesized hydrazinyldiene-chroman-2,4-diones, alone and in 
combination, on viability of MCF-7 breast cancer cells, measured by: a) MTT and b) alamarBlue assay. 
Percentage of viable cells was determined as a ratio of treated cells to controls (C). Results are ex-
pressed as mean ± SD of triplicate experiments. Statistically significant difference when compared to 
the control: *p < 0.05, **p < 0.01; to Doxo-treated cells: #p < 0.05, ##p < 0.01.
a)
b)
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ranging from 69 to 72 % for the lowest (10 µmol L–1) and from 32 to 44 % for the highest 
concentration (100 µmol L–1) used (Fig. 1b) vs. 54 to 62 % and 26 to 30 %, respectively, ob-
tained with the MTT assay (Fig. 1a). In addition, the MTT assay was used (31–56 vs. 41–74 
% with alamarBlue assay) as well as the combination treatment of Doxo (1 µmol L–1) and 
any of the synthesized coumarin derivatives separately (Figs. 1a and b). With the increase 
in the concentration of the coumarin derivative, when it was concomitantly administered 
with Doxo, the effect increased significantly in comparison with the control values, being 
49 % viable cells for the lowest (10 µmol L–1) and 20 % for the highest concentration (100 
µmol L–1) in the MTT assay (Fig. 1a) vs. 53 and 26 % for the lowest and highest concentration 
in the alamarBlue assay (Fig. 1b), respectively. As shown in Fig. 1a, combination treatment 
of 1 µmol L–1 Doxo and 20 µmol L–1 4-HC in MTT and 10–50 µmol L–1 4-HC in the alamar-
Blue assay showed no decrease in cell viability in comparison with Doxo alone. On the 
contrary, the synergy effect of Doxo and coumarin derivatives resulted in a significant cell 
viability decrease by 16–21 % for the lowest (10 µmol L–1) and by 65–71 % for the highest 
(100 µmol L–1) coumarin derivative concentration in MTT, and 8–24 and 53–62 % in the 
alamarBlue assay, resp., when compared to Doxo (1 µmol L–1) alone.
However, as shown in Table II, no significant difference in IC50 of the synthesized com-
pounds was observed when the values from both assays were compared. In addition, sim-
ilar values for IC50 were obtained for all synthesized compounds when they were adminis-
tered alone (approx. 50 µmol L–1) and in combination with Doxo (approx. 20 µmol L–1).
In synergy with Doxo, their IC50 values decreased significantly (p < 0.0001), with the 
coumarin derivative 3-[2-(4,5-dimethyl-1,3-thiazol-2-yl)hydrazinylidene]chroman-2,4-di-
one (1e) being more potent than the other derivatives, but non significantly.
AlamarBlue vs. MTT assay
Non-significant differences in cell viability when the data from the two assays were 
compared can be partly explained by the different sensitivity of assay reagents to the ef-
fects of the compounds on cellular metabolism. Namely, the alamarBlue assay is based on 
Table II. Cytotoxicity of 4-HC and its synthesized derivatives against MCF-7 breast cancer cell lines 
deter mined by MTT and alamarBlue assays
Compound
MTT assay
IC50 (µmol L–1)a
AlamarBlue assay
IC50 (µmol L–1)a
Compound 
alone
Compound+Doxo  
(1 µmol L–1)
Compound 
alone
Compound+Doxo 
(1 µmol L–1)
4-HC > 100 49.668 ± 0.548b > 100 49.838 ± 0.559b
1c 49.784 ± 0.689 20.107 ± 0.768b 49.966 ± 1.167 20.117 ± 1.074b
1d 49.763 ± 0.873 20.067 ± 1.658b 49.802 ± 0.778 20.162 ± 0.902b
1e 49.798 ± 0.864 19.839 ± 0.581b 49.562 ± 0.707 19.851 ± 0.519b
a Mean ± SD from at least three independent experiments.
b Statistically significant difference in IC50 between the compounds applied alone and in synergy with Doxo at 
p < 0.0001.
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the ability of viable and metabolically active cells to reduce the oxidized form of resazurin 
induced in cytosol by various mitochondrial enzymes, by accepting electrons not only 
from NADPH, FADH, FMNH, NADH but also from numerous cytochromes, unlike MTT 
which cannot be reduced to formazan by the cytochromes since its midpoint potential is 
intermediate between that of the electron donors and cytochromes (14). Another factor 
influencing the conversion of MTT to formazan is the number of mitochondria present in 
the cell, with larger cells having more mitochondria and thus showing a higher rate of 
tetrazolium conversion. In addition, defective mitochondria also retain the ability to re-
duce tetrazolium. Thus, all these factors together may lead to false estimation of the cell 
number, suggesting that resazurin is a better redox indicator for cell viability. Different 
cytotoxic effects emerging from assay performance may also explain the observed differ-
ences in cell viability. It is well-known that in the alamarBlue assay, the cells are unaf-
fected by the indicator, remaining fully functional and viable, unlike the MTT assay where 
intracellular formazan crystals must be solubilized with DMSO or HCl/isopropanol for 
quantification, which destroys the investigated cells (14). Different cytotoxic effects were 
also observed by Hamid et al. (15), who evaluated the effects of a wide range of medicines 
in the human hepatoma cell line HepG2 using the two assays. Similarly, in our data, cyto-
toxicity of comparable IC50 values was shown in both assays. Different levels of induction 
and/or inhibition of the metabolic enzymes responsible for transformation of cell toxicity 
end points by the tested compounds could be also a reason for obtaining different results 
from the two assays, as observed for dicumarol (15). In this respect, the fact that 4-HC acts 
as an inhibitor of microsomal mixed function oxidase (16) could explain why the combina-
tion treatment of Doxo and 4-HC did not decrease cell viability in comparison with Doxo 
alone when 4-HC in lower concentrations was administered. Namely, the Doxo bioactiva-
tion network is comprised of a system of reduction/oxidation reactions that lead to forma-
tion of toxic Doxo metabolites and reactive oxygen species (ROSs) responsible for lipid 
peroxidation and membrane damage, DNA damage, oxidative stress and trigger apop-
totic pathways of cell death (2). Reductive conversion of Doxo is characterized by the one-
electron reduction of the quinone moiety of Doxo, via NADPH and cytochrome P450 re-
ductase, into a semiquinone radical. Once the semiquinone radical has been generated, it 
can exert direct toxic effects or be oxidized back to the quinone form. It has been reported 
that the ability of Doxo to undergo reductive conversion is dependent on the availability 
of molecular oxygen and NADPH, and the activities of several intracellular enzymes such 
as superoxide dismutase, glutathione peroxidase and NADPH oxidases. In addition, other 
enzymatic systems are also known to activate Doxo, e.g., xanthine oxidase (XO), DT-dioph-
orase and nitric oxide synthase, to form ROSs. Literature data (17) indicate that certain 
representatives of coumarins are known to inhibit the enzyme XO and are capable of ab-
sorbing ROSs produced by XO and other enzymes.
Induction of apoptosis with synthesized hydrazinyldiene-chroman-2,4-diones and 
doxorubicin
As illustrated in Fig. 2, full PARP (116 kDa) was cleaved into 85 kDa fragments at all 
concentrations of 1c, 1d and 1e alone and in combination with Doxo, which was not ob-
served for the control and 4-HC alone. In addition, the levels of phospho-Thr308Akt were 
down-regulated by the treatment of MCF-7 cells with coumarin derivatives alone or in 
combination with Doxo, when compared to the control treated cells, which correlates with 
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reduced proliferation and increased apoptosis. The same was observed when the apop-
totic effect of these compounds in synergy with tamoxifen was evaluated, where all con-
centrations of 1c, 1d and 1e in synergy with tamoxifen led to reduced protein expression 
of 116 kDa full length PARP and down-regulation of the protein kinase involved in cell 
growth and survival in comparison with the control and combination of tamoxifen and 
4-HC treated cells (13). Similar results were obtained when analogues having coumarin 
and benzimidazole moieties were evaluated for their anticancer activity in different hu-
man cancer cell lines (17). Fluorescence-activated cell sorting and Western blotting analy-
ses identified three compounds that induced caspase-dependent apoptosis. Expression of 
several cancer-related genes (DDIT4, PDGFRA, LRP8, IGFBP5) and Western blotting data 
on key signaling proteins indicated that the compound 7-(diethylamino)-3-(1-methyl-1H-
benzimidazol-2-yl)-2H-chromen-2-one inhibited significantly the PI3K-AKT-mTOR path-
way, an intracellular signaling pathway critical in cell proliferation and apoptosis.
Effect of synthesized hydrazinyldiene-chroman-2,4-diones and doxorubicin on cell cycle 
arrest
It is well known that cell cycle arresting compounds rely on different mechanisms of 
action. Some compounds interfere with the Cdk/cyclin complexes, leaving cells stuck at 
Fig. 2. Western blot analysis of cleaved PARP and phospho-Thr308 Akt after incubation of MCF-7 cells 
with the vehicle (C), 4-HC and synthesized hydrazinyldiene-chroman-2,4-diones: a) alone and b) in 
combination with Doxo for 48 h. Western blot analysis was performed using antibodies against PARP 
(upper panels), phospho-Thr308Akt (middle panels) and the house-keeping protein GAPDH (lower 
panels).
a)
b)
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the G2/M phase border, while the others affect CaMK II phosphorylation, inducing arrest 
at the G1 phase. Other mechanisms of action include interference with RNA function and 
inhibition of protein synthesis.
Effects of the synthesized coumarin derivatives,4-HC and Doxo on cell cycle arrest, 
alone or in combination, are illustrated in Figs. 3a and b. As shown in Fig. 3b, when MCF-7 
cells were exposed to Doxo only (1 µmol L–1), higher percentage of cells were arrested in 
the sub-G1 and G2/M phases. The effect of Doxo on the MCF-7 cell cycle profile was previ-
ously assessed by Bar-On et al. (18), who found that Doxo arrested MCF-7 cells at G1/S and 
G2/M checkpoints, whereas the MDA-MB-231 cells were arrested at G2/M only. Doxo de-
creased the S-phase kinase-associated protein 2 (Skp2) mRNA and protein levels in MCF-
7 cells, but had the opposite effect in MDA-MB-231 cells. In addition, p27 levels were slight-
ly decreased, whereas p53 and p21 levels were significantly upregulated in Doxo-treated 
MCF-7 cells. In contrast, p27 levels were unaffected by Doxo treatment in MDA-MB-231 
cells, but cyclin B levels were markedly increased. Similarly, when the effect of Doxo on 
cell cycle progression and its correlation with DNA damage and cytotoxicity in p53-mu-
tant P388 cells was studied, P388 cells synchronized in S and G2/M phases were > 3-fold 
more sensitive to Doxo than cells in the G1 phase. These results suggest that anthracycline-
induced cytotoxicity is cell-cycle dependent and is mediated, at least in part, by distur-
bance of the regulation of the p34Cdc2/cyclin B1 complex, thus leading to G2/M phase ar-
rest (18). However, when the effects of Doxo in Hct-116 human colon carcinoma cells were 
studied in order to find out if there was a time/concentration range for optimal Doxo-in-
duced apoptosis, continuous (24 h) treatment with 5 µmol L–1 Doxo resulted in cell cycle 
arrest in the G0/G1 phase, which was neither accompanied by phosphorylation and activa-
tion of p53 nor enhanced expression of p21 (19). In contrast, bolus (3 h) treatment resulted 
in a dose-dependent decrease of viable cells and concomitant increase of apoptosis and led 
to phosphorylation of p53 at serine 392, induction of p21, G2 arrest and increase of proapop-
totic protein Bax. These results suggested that Doxo was able to induce cell death by apop-
tosis only under particular dose and treatment conditions and implied a completely dif-
ferent cellular response following bolus or continuous exposure to Doxo (19).
Our results indicate that after treatment with synthesized compounds alone, irrespec-
tive of the concentration used (20 or 50 µmol L–1), higher percentages of the MCF-7 cells 
were arrested in phases when they got ready to duplicate (G1: 68–75 %) and/or get an op-
portunity to repair damage before mitosis (enhanced G2/M peak: 19–30 %) (Fig. 3a). When 
the combination of Doxo (1 µmol L–1) and the compounds in concentration of 50 µmol L–1 
was applied, the number of cells in the S phase decreased, which led to accumulation of 
cells in the G2/M phase. In parallel, more cells containing fragmented DNA were detected 
in the sub-G1 fraction (Fig. 3b). Thus, compared to the compounds alone, the percentage 
of cells in the G2/M phase increased by 14–38 % and in the sub-G1 phase by 89–146 % when 
the combination of Doxo and the compounds was applied (Fig. 3b). This confirmed the 
inhibition of cell growth by cell-cycle arrest in the G2/M phase. These results are partly 
different from the results obtained by Musa et al. (20), who evaluated the cytotoxic activity 
of two acetoxycoumarins against the different cancer cells. The compounds caused cell 
cycle arrest at different phases in the A549 lung and CRL 1548 liver cancer cell lines (S, G2, 
G1), indicating a different mode of cell death or target action for different coumarin de-
rivatives. However, the cytotoxic effects of the synthesized compounds observed in our 
study are in agreement with earlier findings that coumarin and its derivatives inhibit cell 
growth by inducing cell cycle arrest in the G1 phase, obtained by Goel et al. (22) for a lung 
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 19.01.18 17:33
46
L. Ballazhi et al.: Hydrazinyldiene-chroman-2,4-diones in inducing growth arrest and apoptosis in breast cancer cells: Synergism 
with doxorubicin and correlation with physicochemical properties, Acta Pharm. 67 (2017) 35–52.
 
carcinoma cell line and by Alesiani et al. (23) for murine B16 and human A375 melanoma 
cell lines. In addition, in the study of Haghighi et al. (24), 7-isopentenyloxycoumarin ar-
rested cells in the G2/M stage when its effect on cell cycle arrest in transitional cell carci-
noma 5637 cells was studied.
Since it is known that upregulation of cyclin B1/Cdc2 kinase activity is involved in the 
G2/M stage transition of the cell cycle and, on the other hand, cells are arrested in the M 
stage when microtubule network is disrupted, it is possible that the synthesized coumarin 
derivatives acted on the G2 checkpoint or as microtubule inhibitors. This was confirmed 
in several studies (24, 25), which identified the ability of different coumarins to activate 
Fig. 3. Effects of the treatment on cell cycle progression. Cells treated 48 h with either: a) synthesized 
hydrazinyldiene-chroman-2,4-diones alone or b) in combination with Doxo. Results are expressed as 
mean ± SD of triplicate experiments.
a)
b)
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caspase-3, induce internucleosomal DNA laddering fragmentation, and gradually de-
crease the expression of G0/G1-associated proteins and the anti-apoptotic proteins Bcl-2 
and Bcl-xL, while increasing the expression of the pro-apoptotic protein Bax.
Effects of synthesized hydrazinyldiene-chroman-2,4-diones and doxorubicin on cell migration
For cancer development and metastasis, the potential of cells to migrate or to grow 
invasively occurs in addition to proliferation, the most important disease-causing factor. 
Therefore, to assess if coumarin derivatives had any effect on migration ability of the MCF-
7 cells, a wound closure assay was applied and the results are presented in Figs. 4a and b. 
Similarly sized wounds were introduced into monolayer MCF-7 cells at 0 h. In control cells, 
the gap of the wound was filled gradually by migrating cells and 16 h after wound induc-
tion, the gap was almost closed. In contrast, after exposure to synthesized coumarin de-
rivatives, the speed of wound closure was much lower and the wound was still widely 
open at 16 h post exposure (Fig. 4a). On average, wound coverage in the MCF-7 cells was 
45 % after treatment with coumarin derivatives and this percentage significantly decreased 
to 23 % when the compounds were administered in synergy with Doxo (49 % decrease) 
(Fig. 4b). No significant difference between the compounds in suppression of cell migra-
tion was observed in either case. These results are significantly different from the ones 
obtained with Doxo alone (59 %), and 4-HC alone (73 %) and in synergy with Doxo (42 %) 
(Fig. 4b). One can say that the decreased number of migrating cells was a consequence of 
reduced proliferation, since a significant difference was detected between the controls and 
the treated cells in MTT and alamarBlue assays when they were exposed to the same con-
centration of coumarin derivatives (10 µmol L–1) as that used in the migration assay (Figs. 
1a and b). Hence, it should be emphasized that the migration ability of the cells was not 
affected by the antiproliferative effect of the compounds since no significant difference in 
cell viability was detected between the treated cells and the controls in either MTT or ala-
marBlue assay after 16 h, the period during which the effect of coumarin derivatives on 
MCF-7 migration was analyzed.
Fig. 4. Effect of 4-HC and synthesized hydrazinyldiene-chroman-2,4-diones alone and in synergy 
with Doxo on MCF-7 cell migration. a) Photographs of migrating cells, b) summary of wound assay 
results (mean ± SD of triplicate experiments). Statistically significant difference when compared to 
the control (C): *p < 0.05, **p < 0.01; to Doxo-treated cells:  #p < 0.05, ##p < 0.01.
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As the speed of wound closure reflects the migration ability of breast cancer cells, these 
results indicate that treatment with coumarin derivatives can inhibit cell migration. Further-
more, combination treatment of the MCF-7 cells demonstrated additive inhibition of migra-
tion, suggesting that adding coumarin derivatives to a Doxo therapy may further reduce the 
risk of metastasis. Similar results were obtained when certain 7-substituted coumarins (um-
belliferone, scoparone and herniarin) were analyzed for tumor cell motility suppression by 
a wound assay model, where all compounds reduced migration of laryngeal cancer cells in 
a dose-dependent manner (26). In addition, osthole, a natural coumarin derivative (7-me-
thoxy-8-isopentenoxycoumarin), was shown to be effective in inhibiting the migration and 
invasion of breast cancer cells (MCF-7 and MDA-MB 231) in a wound healing assay (27). It 
was proposed that inhibition of matrix metalloproteinase-2 and enzyme activity might be 
one of the causes that led to the inhibition of migration and invasion.
Physicochemical properties of synthesized hydrazinyldiene-chroman-2,4-diones
Physicochemical properties of the synthesized compounds were correlated with their 
structure and cytotoxic activity. Melting points of the synthesized compounds had been 
previously determined and presented and they ranged from approx. 207 (1e) to 219 oC (1d) 
(3, 12). In all the three compounds (1c, 1d, 1e), there are 5 centers of hydrogen bonds; four 
hydrogen bond acceptors (O in position 2 and 4 and N in position 3 of the coumarin ring 
and N in position 1 of the thiazole) and one hydrogen bond acceptor/donor (the third N in 
position 2 of the thiazole). There are two rotatable bonds in all three compounds and zero 
stereo-centers.
According to the predicted pKa values and solubility profile (Table III), conjugate acids 
of investigated compounds are dibasic weak acids. The first pKa value, the value around 4 
experimentally obtained by the two methods, is similar to the predicted one. The proton-
ation site in the molecule of investigated compounds is most probably carbonyl oxygen 
(oxygen in position 2). As regards the second pKa value, it cannot be concluded from the 
appearance of the UV spectra that a second protonation occurs. However, when analyzing 
the shape of the protonation “S” curve in the pH range 2.5-1, i.e., the dependence on the 
maximum absorbance of the absorption band at higher wavelengths originating from the 
thiazole ring, one could assume that the eventual second pKa value is around 1.5. It indi-
cates that the second protonation site would be a nitrogen atom in the thiazole ring. This 
cannot be confirmed or denied by pH-metric titration because of restrictions in the pH 
range in which the pH meter is calibrated. 
Water solubility of the synthesized compounds, expressed in log Sw, ranged from 
–3.80 to –3.46 and it was between –3.66 and –2.46 at the physiological pH 7.4 (Table III). 
Although slight discrepancy was observed between the predicted and experimentally de-
termined values for water solubility (log Sw) and solubility at pH 7.4 (log S7.4) (Table III), a 
high correlation was observed between them (R = 0.957 and R = 0.994, respectively) when 
a simple regression was performed. Among the synthesized compounds, the compound 
3-[2-(1,3-thiazol-2-yl)hydrazinylidene]chroman-2,4-dione (1c) showed the highest water 
solubility and solubility at pH 7.4.
The solubility, pKa and log D7.4 values determined experimentally for monobasic acid 
4-HC were in accord with the literature data (28). In the pH region where pH >> pKa (or pH 
> pKa + 1.5), the equation log D = log P – pH + pKa holds and can be used to estimate the 
partition coefficient of the undissociated monobasic acid (log P) when the pKa value is al-
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ready known. Log P of 4-HC thus obtained was 2.63, which is fairly close to the value of 
2.37 determined by van der Giessen and Janssen (28). Experimentally determined distribu-
tion coefficients (log D7.4exp) of the synthesized compounds ranged between –0.096 (1c) and 
0.602 (1e). As shown in Table III, large discrepancy was noted between the experimentally 
obtained log D7.4exp values and the predicted distribution coefficients log D7.4pred. However, 
when performing a simple regression, a strong correlation between the predicted and 
experimental values (R = 0.999) was found. Discrepancy between the predicted and ex-
perimentally determined values for the distribution coefficients might be caused by the 
tautomeric behavior of the compounds. Possible tautomeric forms of the synthesized hy-
drazinyldiene-chroman-2,4-diones are presented in Scheme 1. As can be seen, the com-
pounds may occur in keto and in enol form.  The exact concentration of each tautomeric 
form is governed by the tautomeric equilibrium, which depends strongly on the medium 
and is therefore different for the aqueous and for the organic phase. This means that keto 
and enol forms may have different lipophilicity, which directly affects the measured dis-
tribution coefficient.
Obviously, introduction of methyl group(s) into the thiazole ring led to a decrease in 
water solubility and increase in lipophilicity, probably due to the inductive character of the 
methyl groups that disfavors ionization. This increase in lipophilicity can drastically mod-
ify the bioavailability, disposition and potency of these compounds. According to the lit-
erature data (29), in a number of cases, the gain in potency was more than 180-fold and in 
all of them the methyl group reorganized the conformation of the ligand for optimal inter-
Table III. Physicochemical properties of synthesized hydrazinyldiene-chroman-2,4-diones
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actions with the receptor. However, no significant difference in potency (IC50) between the 
synthesized compounds was observed in our study. This finding is consistent with the 
conclusions derived from the literature analysis performed by Leung et al. (30). Analysis 
of more than 2000 cases revealed that adding a methyl to a lead compound neither im-
proved nor decreased affinity to the corresponding protein receptors. The authors con-
cluded that to go beyond the 10-fold increase in activity, besides placement of a methyl 
group in a hydrophobic environment, it is also necessary to induce a propitious conforma-
tional change. Therefore, further studies are needed to deduce how the compounds syn-
thesized in our study interact with the receptors and also how they are absorbed and 
distributed on their way to the receptors.
CONCLUSIONS
Hydrazinyldiene-chroman-2,4-diones having thiazole moiety without or with addi-
tional methyl group(s) attached to the carbon(s) at position(s) 5 and/or 4 in the thiazole ring 
can effectively inhibit proliferation of MCF-7 cells, inhibit cell migration and induce chroma-
tin condensation, DNA damage and caspase-dependent apoptosis, and arrest the cell cycle 
at the G2/M stage. In the presence of Doxo, the potency of these compounds increases. With 
their solubility profile and log D7.4, all three compounds follow Lipinski’s rule of five for 
good permeability (absorption) potential, log D7.4 less than 5, molecular mass less than 500 
Da, fewer than 5 hydrogen bond donors and fewer than 10 hydrogen bond acceptors. The 
coumarin derivative 3-[2-(4,5-dimethyl-1,3-thiazol-2-yl)hydrazinylidene]chroman2,4-dione 
(1e) shows the lowest water solubility at pH 7.4, highest lipophilicity and slightly higher 
potency than the other derivatives, without or with one methyl group attached to the thia-
zole moiety in position 4. Further studies are needed to determine their permeability and 
transport interactions, pharmacokinetic properties and exact mechanisms of action.
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List of acronyms, symbols and codes. – A375 – human melanoma cell line, A549 – human lung cancer 
cell line, B16 – murine melanoma cell line, Bax – Bcl-2-associated X protein, Bcl-2 – B-cell lymphoma 2 
protein, Bcl-xL – B-cell lymphoma-extra-large protein, CaMK II – calcium/calmodulin-dependent pro-
tein kinase II, Cdc2 kinase – cyclin-dependent protein kinase Cdk1/Cdc2, Cdk – cyclin-dependent ki-
nase, CRL 1548 – rat liver cancer line, DDIT4 – DNA damage inducible transcript 4, DMEM – Dulbesco’s 
modified Eagle’s medium, Doxo – doxorubicin, FADH – flavin adenine dinucleotide, FBS – fetal bovine 
serum, FMNH – semiquinone form of flavin mononucleotide, FoxM1 – Forkhead Box M1, GAPDH - 
glyceraldehyde-3-phosphate dehydrogenase, Hct-116 – human colon carcinoma cell line, HepG2 – hu-
man liver cancer cell line, IGFBP5 – insulin like growth factor binding protein 5, LRP8 – LDL receptor 
related protein 8, MAPK – ATP p38 mitogen activated protein kinase, MCF-7 – human breast adenocar-
cinoma cell line, MCF-7R – multidrug-resistant variant of MCF-7 cell line, MDA-MB-231 – human breast 
adenocarcinoma cell line, MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, NADH 
– nicotinamide adenine dinucleotide, NADPH – nicotinamide adenine dinucleotide phosphate, P388 
– mouse leukemia cells, PARP – poly (ADP-ribose) polymerase, PDGFRA – platelet derived growth 
factor receptor alpha, Phospho-Thr308Akt – protein kinase Akt phosphorylated at threonine 308, PI – 
propidium iodide, PI3K-AKT-mTOR – phosphatidylinositol-3-kinase-Akt-mammalian target of rapa-
mycin, PMSF – phenylmethylsulfonyl fluoride, SCP1833 – bone metastatic cell line from breast cancer, 
SCP4175 – lung metastatic cell line from breast cancer, Skp2 – S-phase kinase-associated protein 2, 
STAT3 – signal transducer and activator of transcription 3.
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